Features in 2018

Filter By:

Article Type
Year

  • Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand monopolies for mAbs and other biologics.

    • Gary Walsh
    Feature

  • A group of microbiome researchers discuss some of the challenges in developing a new generation of microbiome therapies.

    • Gaspar Taroncher-Oldenburg
    • Susan Jones
    • Jun Wang
    Feature

  • Last year, investors scrambled to invest in newly floated biotechs. This, together with a brisk licensing market and policy tailwinds, helped boost the sector, even as an expected M&A boom was late to materialize.

    • Chris Morrison
    • Riku Lähteenmäki
    Feature

  • More investors are building companies from scratch, with more money than any time in biotech's history.

    • Brady Huggett
    Feature

  • Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine.

    • Malorye Allison Branca
    • Ken Garber
    • Laura DeFrancesco
    Feature